US8684591089
US8684591089
Supernus Pharmaceuticals, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 2.48B EUR | 2.71B EUR | 3B EUR | 2.86B EUR |
Enterprise Value | 2.12B EUR | 2.57B EUR | 2.86B EUR | 2.77B EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | 9.57x | -- | -- | -- |
Price to Sales | 2.99x | 3.26x | 3.86x | 5.02x |
Price to Book | 2.41x | 2.62x | 2.79x | 2.69x |
EV/Revenue | 2.55x | 3.09x | 3.68x | 4.86x |
EV/EBITDA | 19.18x | 45.07x | 41.03x | 58.86x |
Price to FCF (P/FCF) | 29.36x | 143.99x | 36.48x | 181.64x |
EV/FCF | 25.03x | 136.55x | 34.73x | 176.08x |
FCF Yield | 3.41% | 0.69% | 2.74% | 0.55% |